Esculetin inhibited PI3K/Akt/mTOR pathway and enhances anti-colorectal cancer activity via binding to ENO1

Colorectal cancer (CRC) is the third most common malignant tumor globally and the second leading cause of cancer-related deaths. Currently, although the standard treatment for CRC is a combination of surgery and chemotherapy, metastasis and recurrence are often associated with a poor prognosis. In our preliminary research, we found that Esc has anti-colon cancer effects both in vivo and in vitro. However, its specific target sites and molecular mechanisms still lack in-depth exploration and remain unclear. Therefore, we employed transcriptomics technology to analyze the complex interactions between the drug and its targets, thereby conducting a comprehensive evaluation. To elucidate the molecular mechanisms underlying the anti-tumor properties of Esc in colorectal cancer, we performed RNA sequencing for whole-genome expression analysis on HCT116 cell samples treated with Esc. Through enrichment analysis of differentially expressed genes, we revealed that Esc is likely to intervene in th..., , # Esculetin inhibited PI3K/Akt/mTOR pathway and enhances anti-colorectal cancer activity via binding to ENO1

Dataset DOI: [10.5061/dryad.d7wm37qd2 ](10.5061/dryad.d7wm37qd2)

## Description of the data and file structure

Illumina, Library preparation, PubChem, Transcriptome Sequencing data

#### Files and variables

**File: Data_4B.xlsx**

Description: Differential gene expression heatmap

This table presents the similarities and differences in gene expression patterns between the Esc and Ctrl groups. The data are standardized using Z-score normalization, where positive Z-scores (indicated in red) represent high expression levels, and negative Z-scores (indicated in blue) represent low expression levels.

**File: Data_4A.xlsx**

Description: Principal Component Analysis (PCA) Data among Samples

This table describes the similarity among samples in the Esc and Ctrl groups.

**Variables**

geneID: A unique identifier...,